Glycemic and Inflammatory status of Type2 Diabetes after Antiviral Therapy for HCV
Not Applicable
Not yet recruiting
- Conditions
- hepatitis C virus HCVNutritional, Metabolic, EndocrineDiabetes T2
- Registration Number
- PACTR201712002777310
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
100 Patients diagnosed with type 2 diabetes and HCV-GT4 and treated with two direct antiviral agents (DAAs) will be follow up at 1-baseline, 2-after treatment(12 wks) and 3-12 wks after the end of treatments
Exclusion Criteria
Patients with other infectious diseases, autoimmune disorders, asthma, eczema, allergies, thyroid diseases, kidney failure, liver decompensation and alcohol abuse will be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method